Immune checkpoint inhibitors in melanoma
Immune checkpoint inhibitors target the dysfunctional immune system, to induce cancer-cell
killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and …
killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and …
Mechanisms of immune activation and regulation: lessons from melanoma
Melanoma, a skin cancer that develops from pigment cells, has been studied intensively,
particularly in terms of the immune response to tumours, and has been used as a model for …
particularly in terms of the immune response to tumours, and has been used as a model for …
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial …
PURPOSE Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4–
blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in …
blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in …
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical
efficacy in BRAFV600E colorectal cancer (CRC), response rates remain low and lack …
efficacy in BRAFV600E colorectal cancer (CRC), response rates remain low and lack …
Beyond immune checkpoint blockade: emerging immunological strategies
The success of checkpoint inhibitors has accelerated the clinical implementation of a vast
mosaic of single agents and combination immunotherapies. However, the lack of clinical …
mosaic of single agents and combination immunotherapies. However, the lack of clinical …
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis …
R Gutzmer, D Stroyakovskiy, H Gogas, C Robert… - The Lancet, 2020 - thelancet.com
Background IMspire150 aimed to evaluate first-line combination treatment with BRAF plus
MEK inhibitors and immune checkpoint therapy in BRAF V600 mutation-positive advanced …
MEK inhibitors and immune checkpoint therapy in BRAF V600 mutation-positive advanced …
Independent drug action in combination therapy: implications for precision oncology
Combination therapies are superior to monotherapy for many cancers. This advantage was
historically ascribed to the ability of combinations to address tumor heterogeneity, but …
historically ascribed to the ability of combinations to address tumor heterogeneity, but …
The future of cancer immunotherapy: microenvironment-targeting combinations
YR Murciano-Goroff, AB Warner, JD Wolchok - Cell research, 2020 - nature.com
Immunotherapy holds the potential to induce durable responses, but only a minority of
patients currently respond. The etiologies of primary and secondary resistance to …
patients currently respond. The etiologies of primary and secondary resistance to …
Tumour-intrinsic resistance to immune checkpoint blockade
Abstract 'Immune checkpoint blockade'for cancer describes the use of therapeutic antibodies
that disrupt negative immune regulatory checkpoints and unleash pre-existing antitumour …
that disrupt negative immune regulatory checkpoints and unleash pre-existing antitumour …
NCCN Guidelines® insights: melanoma: cutaneous, version 2.2021: featured updates to the NCCN guidelines
SM Swetter, JA Thompson, MR Albertini… - Journal of the National …, 2021 - jnccn.org
Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been
expanded to include pathways for treatment of microscopic satellitosis (added in v2. 2020) …
expanded to include pathways for treatment of microscopic satellitosis (added in v2. 2020) …